ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling

Targeting androgen signaling with the second-generation anti-androgen drugs, such as enzalutamide (Enza), abiraterone (Abi), apalutamide (Apal), and darolutamide (Daro), is the mainstay for the treatment of castration-resistant prostate cancer (CRPC). While these treatments are effective initially,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chengfei, Armstrong, Cameron M., Ning, Shu, Yang, Joy C., Lou, Wei, Lombard, Alan P., Zhao, Jinge, Wu, Chun-Yi, Yu, Aiming, Evans, Christopher P., Tepper, Clifford G., Li, Pui-kai, Gao, Allen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413131/
https://www.ncbi.nlm.nih.gov/pubmed/34272475
http://dx.doi.org/10.1038/s41388-021-01914-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413131/
https://www.ncbi.nlm.nih.gov/pubmed/34272475
http://dx.doi.org/10.1038/s41388-021-01914-2

Ejemplares similares